Analyst Reco. Veracyte, Inc.

Equities

VCYT

US92337F1075

Real-time Estimate Cboe BZX Other stock markets 01:31:10 2024-06-03 pm EDT			5-day change	1st Jan Change
20.98 ^USD	+1.13%		-2.94%	-24.32%

May. 07	Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	MT
May. 07	Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	Feb. 26	MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating	Feb. 23	MT
Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating	Nov. 10	MT
Goldman Sachs Cuts Veracyte's Price Target to $32 From $37, Keeps Buy Rating	23-10-23	MT
Morgan Stanley Adjusts Price Target on Veracyte to $23 From $22, Maintains Underweight Rating	23-08-09	MT
Needham Adjusts Price Target on Veracyte to $35 From $34, Maintains Buy Rating	23-08-09	MT
Needham Adjusts Price Target on Veracyte to $34 From $33, Keeps Buy Rating	23-02-23	MT
Raymond James Downgrades Veracyte to Market Perform From Outperform	23-01-18	MT
Scotiabank Initiates Veracyte at Sector Outperform Rating With $33 Price Target	23-01-05	MT
Scotiabank Initiates Veracyte at Sector Outperform With $33 Price Target	23-01-05	MT
Raymond James Adjusts Price Target on Veracyte to $27 From $31, Maintains Outperform Rating	22-11-04	MT
SVB Securities Adjusts Veracyte's Price Target to $35 From $30, Keeps Outperform Rating	22-11-03	MT
Needham Adjusts Price Target on Veracyte to $33 From $31, Maintains Buy Rating	22-11-03	MT
Raymond James Adjusts Veracyte's Price Target to $31 from $30 Keeps Outperform Rating	22-08-04	MT
Goldman Sachs Cuts Price Target on Veracyte to $32 From $35, Noting Decline in Peer Multiples; Buy Rating Maintained	22-08-04	MT
Needham Adjusts Veracyte's Price Target to $31 From $26, Citing 'Peer Multiple Expansion,' Reiterates Buy Rating	22-08-03	MT
Morgan Stanley Adjusts Veracyte's Price Target to $23 from $25, Keeps Underweight Rating	22-05-04	MT
Raymond James Adjusts Veracyte's Price Target to $30 from $34, Keeps Outperform Rating	22-05-04	MT
Needham Adjusts Veracyte's Price Target to $26 From $31 on Peer Multiple Compression, Reiterates Buy Rating	22-05-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Veracyte, Inc.

Equities

VCYT

US92337F1075

Analyst Reco.

Filters